Hims & Hers Health operates an asset-light telehealth platform leveraging subscription services, cross-selling and personalization to drive average revenue per user (ARPU) up by more than 25% year-over-year in Q3. Strong retention—over 85% for core services—and structurally low customer acquisition costs (below $45 per subscriber) have led to improving unit economics. Weight-loss programs now account for nearly 30% of total subscriptions, diagnostic testing contributes 15%, and recently launched international services represent 10% of new sign-ups, underpinning sustained ~50% revenue growth despite a broader market growth slowdown.

While revenue growth has normalized from triple-digit rates, adjusted EBITDA margins remain in a healthy mid-teens range, reflecting deliberate investments in platform enhancements rather than pricing pressure. Free cash flow turned positive in the last quarter, driven by tighter working capital management and marketing efficiency improvements—marketing spend per incremental subscriber fell by 10% sequentially. The company’s cash flow profile supports continued product development without diluting shareholders, and management reiterates a path to breakeven at the consolidated level by late 2025.

Following a roughly 45% share-price correction since early 2024 highs, Hims & Hers sits on a robust balance sheet with liquidity exceeding $1.1 billion, including cash, short-term investments and undrawn credit facilities. The reset in valuation has created a rare growth-at-a-reasonable-price setup, with shares trading close to 15x forward EV/EBITDA versus peer averages above 25x. Given the company’s proven track record of doubling revenues annually in a new vertical like 'Hers' products and ongoing international rollouts, investors have an opportunity to capture high-growth cash flows at a material discount to historical multiples.